Completed PHASE3 INTERVENTIONAL 2-arm NCT00018174

Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers

Sponsor: Eli Lilly and Company

Interventions Behavioral group smoking cessation treatment Fluoxetine Placebo

Updated 6 times since 2017 Last updated: Feb 26, 2009 Started: Feb 28, 1998 Primary completion: Jan 31, 2003 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Depression and Smoking and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Aug 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
US Department of Veterans Affairs

Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hines, United States